Abu Dhabi Health Department Signs MoU with Xlife Sciences to Boost Life-Sciences Sector

By Danélia Botes

September 12, 2023

The Department of Health – Abu Dhabi (DoH) and Swiss firm Xlife Sciences have signed a Memorandum of Understanding (MoU) in a bid to fortify the Emirate’s life-sciences sector. The agreement, which was signed at the Department’s Headquarters, aims to enhance innovation, funding opportunities for life sciences start-ups, and clinical research within the Emirate.

The collaboration is part of DoH’s ongoing efforts to establish Abu Dhabi as a global hub for healthcare and life sciences. It will provide incubation training, mentoring, and commercialisation support to innovators, while also exploring the possibility of a joint funding framework with local ecosystem partners.

Dr. Asma Ibrahim Al Mannaei, Executive Director of Research and Innovation Centre at the DoH, expressed her delight at the collaboration, citing it as a step towards addressing global healthcare challenges and reinforcing the development of Abu Dhabi’s life sciences sector.

Xlife Sciences, represented by CEO Oliver R. Baumann, has established their UAE presence through a partnership with ICEBERG Capital, a company based in Abu Dhabi Global Market (ADGM) and regulated by Financial Services Regulatory Authority (FSRA). ICEBERG Capital will be handling the company’s investment strategy and fund management, further enhancing the life sciences ecosystem in Abu Dhabi.

Abdullah Al Weshah, Managing Director – ICEBERG Capital, commented on the collaboration, expressing excitement at the prospect of supporting the Abu Dhabi Life-Sciences ecosystem and looking forward to establishing a joint funding framework to support start-ups, founders, and projects.

This agreement further cements Abu Dhabi’s position as a global life sciences hub and an incubator for healthcare innovation, while spearheading the transformation of the regional healthcare ecosystem through leveraging sciences and technology. 

Reference url

Recent Posts

Pharmacogenetic Screening
            

Pharmacogenetic Screening: A Cost-Effective Strategy in Treating Major Depressive Disorder

🔍 Discover the cost-effectiveness of pharmacogenetic screening in treating Major Depressive Disorder (MDD).
This approach could save costs and improve patient outcomes in the Spanish National Health System. Read more to understand the potential benefits and future implications. 🌐💡
#SyenzaNews #Pharmacogenetics #MajorDepression #CostEffectiveness #HealthcareInnovation

                 

Healthy Ageing Index and Assessment of Age-Related Outcomes

🌟 Healthy Ageing Index and Assessment of Age-Related Outcomes 🌟

📊 Unlocking the Secrets of Healthy Ageing in Singapore! Discover the significance of the Healthy Ageing Index (HAI) in predicting age-related outcomes! Learn how this tool can help promote healthy ageing and improve quality of life. 👵👴

#SyenzaNews #HealthyAgeing #SingaporeHealthcare #AgeingPopulation #HealthOutcomes

Thailand's healthcare system
              

Thailand’s Healthcare System and the Role of HTA: A Model of Universal Health Coverage

Thailand’s healthcare system is a beacon of efficiency and effectiveness. Achieving Universal Health Coverage in 2002, the country has made remarkable strides in health outcomes, despite spending less compared to other upper-middle-income countries.

Learn how Thailand’s use of Health Technology Assessment (HTA) has played a crucial role in this success and the future steps to address current challenges. 🌍💉

#SyenzaNews #Healthcare #UniversalHealthCoverage #HTA #Innovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

JOIN NEWSLETTER




SERVICES

© 2024 Syenza™. All rights reserved.